Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Garber

Showing results (101-110 of 194) with videos related to

Pageof 20
Sort By:
Nature Biotechnology|September 13, 2017
Adenosine checkpoint agent blazes a trail, joins immunotherapy rosterKen Garber
Nature Reviews. Drug Discovery|June 21, 2024
Menin inhibitors seek to debut as newest targeted therapy for leukaemiaKen Garber
Nature Biotechnology|January 11, 2013
Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis marketKen Garber
Nature Biotechnology|June 12, 2013
Galecto BiotechKen Garber
Journal of the National Cancer Institute|November 26, 2009
Companies waver in efforts to target transforming growth factor beta in cancerKen Garber
Nature Medicine|February 1, 2002
Controversial allocation rules for liver transplantsKen Garber
Nature Biotechnology|October 12, 2016
Big win possible for Ionis/Biogen antisense drug in muscular atrophyKen Garber
Nature Biotechnology|June 10, 2015
Alnylam's RNAi therapy targets amyloid diseaseKen Garber
Science (New York, N.Y.)|July 11, 2015
BIOMEDICINE. Targeting copper to treat breast cancerKen Garber
Nature Biotechnology|July 2, 2003
Sugen falls as casualty of Pfizer-Pharmacia mergerKen Garber
Pageof 20

Showing results (101-110 of 194) with videos related to

Sort By:
Pageof 20
Nature Biotechnology|September 13, 2017
Adenosine checkpoint agent blazes a trail, joins immunotherapy rosterKen Garber
Nature Reviews. Drug Discovery|June 21, 2024
Menin inhibitors seek to debut as newest targeted therapy for leukaemiaKen Garber
Nature Biotechnology|January 11, 2013
Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis marketKen Garber
Nature Biotechnology|June 12, 2013
Galecto BiotechKen Garber
Journal of the National Cancer Institute|November 26, 2009
Companies waver in efforts to target transforming growth factor beta in cancerKen Garber
Nature Medicine|February 1, 2002
Controversial allocation rules for liver transplantsKen Garber
Nature Biotechnology|October 12, 2016
Big win possible for Ionis/Biogen antisense drug in muscular atrophyKen Garber
Nature Biotechnology|June 10, 2015
Alnylam's RNAi therapy targets amyloid diseaseKen Garber
Science (New York, N.Y.)|July 11, 2015
BIOMEDICINE. Targeting copper to treat breast cancerKen Garber
Nature Biotechnology|July 2, 2003
Sugen falls as casualty of Pfizer-Pharmacia mergerKen Garber
Pageof 20